African American patients with gout: efficacy and safety of febuxostat vs allopurinol. - Test2 - elhamkhani - TriplyDB

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

http://www.wikidata.org/entity/Q34153554

about

Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout.Racial and gender disparities among patients with gout.Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout.Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.Developing and proposing the ethno-cultural gerontological nursing model.Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.

P2860

Q34153529-C2B65BCB-CFC8-4EDA-BEA5-8E76197E99BC Q34502543-32AC6E4A-C975-47EF-A615-7CAC22297318 Q36533940-2598A3DC-9780-481C-A5E6-34B32DA09310 Q38365938-E48455F7-15CA-44BF-B947-7A789BB68492 Q38853112-A9CC9ED3-4A8D-4744-9A5F-6CF0A3E901EA Q39073349-FB463A08-4067-4E45-BDA1-0CBCCE5F392A Q47690427-5E363E65-5543-4373-8FDB-DB791B0D6B41 Q53491436-752F0EB2-88CC-4E28-9165-6CA4C61DD566

P2860

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

http://www.wikidata.org/entity/Q34153554

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

@ast

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

@en

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

@nl

type

label

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

@ast

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

@en

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

@nl

prefLabel

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

@ast

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

@en

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

@nl

P1433

Q34153554-8655F534-862C-4253-A05F-4B5FCD1495DF

P1476

Q34153554-8DDECF92-2AB6-4B4A-81A7-AE3505140E6B

P2093

Q34153554-44E6F382-DE94-4A3B-9A8D-0620EF951051

Q34153554-704AE2E0-CFE7-41F3-A69B-9B3F6CFE4170

Q34153554-81B32381-88D6-483D-BD81-FF55761F2262

Q34153554-8C09ADB5-2B83-4B81-B667-207C984C00AC

P2860

Q34153554-000BD4FA-EFB2-4AFA-97E8-26EA42A156E3

Q34153554-0599807E-FC1D-456F-B87C-C68FCD41B538

Q34153554-0982AB9F-C3E1-4363-A11F-584681D427E0

Q34153554-0B5715F4-486A-4418-A599-B71C16052480

Q34153554-1C91DBAB-C132-42A4-885A-FEFD9B227C8A

Q34153554-1D30008E-9E1D-49BD-A5F3-8E7E70CE24B4

Q34153554-27720BFA-C2D1-4406-82CA-B27162FBD904

Q34153554-2A1A8AA1-4AF7-43C5-B809-675E7DA56034

Q34153554-35A2A2EB-A14B-4BB2-A0C4-9770F9B45169

Q34153554-3A73538C-B28B-4FB9-82E1-88971FFEA58B

P2888

Q34153554-05693EBB-B84D-4949-B073-7F815E7DCD1B

P304

Q34153554-1A10F8DD-E071-4298-8FEE-A22727CE8C0D

P31

Q34153554-EDA9CE28-5DB7-4EFA-83DB-E766C63E4118

P356

Q34153554-59B9AC5C-D2B4-47DE-8493-430F4672CCAF

P478

Q34153554-ED04B20E-A59F-44B3-BA1F-47AE11D25393

P577

Q34153554-1F3B7E94-2A54-47DA-91A2-6ECEA109F1F5

P5875

Q34153554-805371AC-1122-4BBF-9324-B9010CCFADB8

P6179

Q34153554-AFC0711B-FCB8-4E45-8B0E-29000FD4DCEF

P698

Q34153554-DEC4DC3E-B61F-46BD-840F-3ED187245EB2

P932

Q34153554-C20248B8-52F8-42CF-9CA0-03A6C903C71B

P356

1471-2474-13-15

P1433

BMC Musculoskeletal Disorders

P1476

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

@en

P2093

Alvin F Wells

http://www.w3.org/2001/XMLSchema#string

Patricia A MacDonald

http://www.w3.org/2001/XMLSchema#string

Robert L Jackson

http://www.w3.org/2001/XMLSchema#string

Solomon Chefo

http://www.w3.org/2001/XMLSchema#string

P2860

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

Pathogenesis of Gout

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Gout and the risk of acute myocardial infarction

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

Prediction of creatinine clearance from serum creatinine

Allopurinol treatment and its effect on renal function in gout: a controlled study

Understanding why rheumatoid arthritis patient treatment preferences differ by race.

A genome-wide association study of serum uric acid in African Americans.

P2888

1471-2474-13-15

P304

15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2474-13-15

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221816179

http://www.w3.org/2001/XMLSchema#string

P6179

1036953300

http://www.w3.org/2001/XMLSchema#string

P698

22316106

http://www.w3.org/2001/XMLSchema#string

P932

3317813

http://www.w3.org/2001/XMLSchema#string